BioNTech's New Helmsman Faces a Halved Forecast and a Factory Shutdown Spree
Published on 08/07/2026 at 17:51 | Redaktion boerse-global.de
The handover at BioNTech's helm is happening at a moment of maximum strain. With co-founder U?ur ?ahin set to depart by February 2027 — alongside his wife and fellow executive Özlem Türeci, who is launching a new mRNA venture — the Mainz-based biotech has tapped Guido Oelkers, the outgoing CEO of Swedish pharma group Sobi, to steer the company through its post-pandemic reinvention.
Oelkers inherits a balance sheet in transition. Second-quarter revenue collapsed to €106 million, down from €261 million in the same period last year and roughly 32 percent shy of analyst expectations. The quarterly net loss widened to €821 million, compared with €387 million a year earlier. For the first half of 2026, the cumulative net loss reached €1.35 billion — a 68 percent jump from the €824 million recorded in the prior-year period.
The deterioration is a direct reflection of the fading COVID-19 franchise that once defined the company. Management has responded by trimming its full-year revenue guidance to a range of €1.6 billion to €1.9 billion, down from the previously communicated €2.0 billion to €2.3 billion. Research spending is also being scaled back, with the 2026 budget now set at €2.0 billion to €2.3 billion, versus an earlier plan of €2.2 billion to €2.5 billion.
The cost discipline extends beyond the income statement. BioNTech plans to shutter its production sites in Idar-Oberstein, Marburg and TĂĽbingen by the end of 2027, with the Singapore facility following in the first quarter of that year. The closures underscore how aggressively the company is recalibrating its footprint to match a dramatically smaller revenue base.
Should investors sell immediately? Or is it worth buying BioNTech?
Wall Street has responded by marking down its expectations. A group of 17 analysts has cut the 2026 revenue estimate to €1.86 billion from €2.17 billion, while the projected loss per share has widened to €5.45 from €4.40. The second-quarter loss per share came in at €3.24, overshooting the consensus forecast by 55 percent.
Yet the average price target remains frozen at $121, with individual estimates ranging widely from $76.23 to $148. That dispersion captures the fundamental disagreement among investors: some see the pipeline beyond COVID vaccines as a compelling growth story, while others question how quickly new revenue streams can materialize.
Oelkers arrives with a commercial track record that contrasts sharply with ?ahin's scientific pedigree. At Sobi, he oversaw the roughly $915 million acquisition of Dova, the licensing of Synagis, and the launch of Altuviiio. His stated ambition at BioNTech: multiple approved products by 2030 — a target that now falls squarely on his shoulders.
BioNTech at a turning point? This analysis reveals what investors need to know now.
Market reaction to the news has been notably muted. Despite the missed estimates and reduced guidance, the stock traded up 3.04 percent at €81.45 in German markets on Friday morning, hovering about 2.29 percent above its 50-day average of €79.62. The shares remain more than 23 percent below their 52-week high of €105.80, reached in January. At the Nasdaq close on Thursday, the ADR finished at $91.19, down 1.07 percent on the day. In Frankfurt, the stock was recently changing hands at €79.05, roughly 25 percent off that January peak, and sits about six percent below its 200-day average of €84.11 — a sign that the broader downtrend has yet to reverse despite a modest 0.57 percent weekly gain.
The market's equanimity suggests investors are pricing in the leadership change as a catalyst for renewal, with the disappointing quarterly numbers already baked into the share price. Whether that optimism proves justified will depend on how quickly Oelkers can articulate a strategy that moves BioNTech beyond its pandemic-era identity — and whether the pipeline can deliver before the cash burn becomes a more pressing concern.
Ad
BioNTech Stock: New Analysis - 7 August
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
